Expression of mir-29b-3p relapsing-remitting multiple sclerosis responders and nonresponders to interferon beta therapy

Mahtab Fattahi sadegh abadi,1,* Nahid eskandari,2 Fattah sotoodehnejadnematalahi ,3 Vahid shaygannejad,4

1. Department of Biology,school of Basic Science ,Science and research branch, Islamic Azad University,poonak, Tehran, Iran
2. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3. Department of Biology,school of Basic Science ,Science and research branch, Islamic Azad University,poonak, Tehran, Iran
4. Department of Neurology, Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Introduction

Multiple sclerosis (ms) is a chronic, inflammatory and demyelinating disease that affects the central nervous system. th17 andth1 cells are the main cells of inflammatory process in ms. mirnas are likely involved in most biological processes, and play important roles in the immune system function. the purpose of this study was to evaluate mir-29-3pexpression in responders and nonresponders patients to interferon beta treatment.

Methods

A total of 70 patients including responders and non-responders to interferon b (inf-b) (n=35) were enrolled. we analyzed the expression level of mir-29-3p using peripheral blood from rr-ms patients at 12 months after starting with ifn-β therapy. real-time qpcr was performed to analyze mir-29-3p expression.

Results

These results indicated that mir-29-3p expression was reduced in responders compared to controls, but this downregulation wasn’t seen in non-responders. furthermore, the level of mir-29-3p was significantly decreased in responders compared to nonresponders (p < 0.05).

Conclusion

: mir-29-3p expression is associated with chronic inflammatory responses in ms. therefore, reduction of its expression may link to the downregulation of inflammation. overall, mir-29-3p expression levels might act as a marker of the biological effects of ifn-β therapy.

Keywords

Interferon-beta; multiple sclerosis; mir-29-3p